Perimeter Medical Imaging AI (PINK) Investor Update summary

Technology and product overview

• Two main products: S-Series (FDA-cleared, commercial use) and B-Series (in clinical trial, investigational use).

• Core technology is OCT imaging, offering high-resolution, real-time visualization of tissue margins during surgery.

• AI algorithms are being developed to assist surgeons in identifying positive margins more efficiently.

• Proprietary image library and strong IP protection create a significant competitive moat.

Clinical impact and evidence

• OCT technology reduces reoperation rates in breast cancer surgery from 20% nationally to 5.6% in a recent study.

• Particularly strong results in invasive ductal carcinoma, with some subgroups seeing zero reoperations.

• Ongoing studies and papers are expanding evidence base, including applications in head and neck cancer.

• Surgeons across experience levels have adopted the technology, reporting positive patient outcomes.

Market opportunity and business model

• U.S. breast cancer re-excisions cost nearly $700M annually; technology could save up to $500M per year.

• Total addressable market expands to over $1B annually across top eight cancers.

• Business model combines device placement with high-margin consumables and recurring revenue.

• Additional revenue from service, maintenance, and potential device sales as adoption grows.